ArticleFrontiers in microbiology2019
Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- How social is social resistance?Essays in biochemistry · 2026Review
- Antibiotic Exposure and Periodontal Susceptibility: A Risk-Modifying Hypothesis.International journal of molecular sciences · 2026Review
- Antibiotic-induced gut microbiome dysbiosis: risks and strategies for mitigation.The EMBO journal · 2026Review
- The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nature reviews. Drug discovery · 2025Review
- Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.Biomedicines · 2025Review
- Cooperative resistance varies among β-lactamases in E. coli, with some enabling cross-protection and sustained extracellular activity.Communications biology · 2025Article
- Review
- Dynamic Effect of β-Lactam Antibiotic Inactivation Due to the Inter- and Intraspecies Interaction of Drug-Resistant Microbes.ACS biomaterials science & engineering · 2024Article
- Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.JAMA network open · 2023Article
- Gut Microbiota Modulation and Prevention of Dysbiosis as an Alternative Approach to Antimicrobial Resistance: A Narrative Review.The Yale journal of biology and medicine · 2022Review
- Article
- Intestinal Exposure to Ceftiofur and Cefquinome after Intramuscular Treatment and the Impact of Ceftiofur on the Pig Fecal Microbiome and Resistome.Antibiotics (Basel, Switzerland) · 2022Article
- Effects of laboratory domestication on the rodent gut microbiome.ISME communications · 2021Article
- Gut microbiota of frugo-folivorous sifakas across environments.Animal microbiome · 2021Article
- Aging-Induced Dysbiosis of Gut Microbiota as a Risk Factor for IncreasedFrontiers in immunology · 2021Article
- Article
- State-of-the-Art of the Nutritional Alternatives to the Use of Antibiotics in Humans and Monogastric Animals.Animals : an open access journal from MDPI · 2020Review
- Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia.Translational research : the journal of laboratory and clinical medicine · 2020Review
- The global preclinical antibacterial pipeline.Nature reviews. Microbiology · 2020Review
- Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review.Microorganisms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics can damage the gut microbiome, leading to serious adventitious infections and emergence of antibiotic resistant pathogens. Antibiotic inactivation in the GI tract represents a strategy to protect colonic microbiota integrity and reduce antibiotic resistance. Clinical utility of this approach was established when SYN-004 (ribaxamase), an orally-administered beta-lactamase, was demonstrated to degrade ceftriaxone in the GI tract and preserve the gut microbiome. Ribaxamase degrades penicillins and cephalosporin beta-lactams, but not carbapenems. To expand this prophylactic approach to include all classes of beta-lactam antibiotics, a novel carbapenemase, formulated for oral administration, SYN-006, was evaluated in a porcine model of antibiotic-mediated gut dysbiosis. Pigs (20 kg,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.